Europe Series B+ Weekly Funding Roundup (May 4-11, 2026): $208.0M Raised Across 2 Deals

Table of Contents

European Series B+ activity totaled $208M across two deals between May 4 and May 11, 2026. Both rounds went to deeptech and healthtech companies with strategic backing, signaling that European late-stage capital is concentrating on technical moats and sovereign-relevant categories rather than software growth stories.

The week's marquee deal was a Delft-based quantum processor company pulling $178M with Intel Capital and In-Q-Tel on the cap table, the largest private round ever for an industrial QPU supplier. A German AI-driven drug development company added $30M through the European Innovation Council's STEP Scale Up scheme, reflecting Brussels' push to keep frontier biotech IP on the continent.

1. QuantWare Raises $178M Series B For Quantum Processors

Deal Overview

• Stage: Series B
• Sector: Deeptech, quantum hardware
• Geography: Delft, Netherlands
• Round size: $178M (€152M)
• Investors: Intel Capital, In-Q-Tel, ETF Partners, FORWARD.one, Invest-NL Deep Tech Fund, InnovationQuarter Capital, Ground State Ventures, Graduate Ventures

Investor Profile

Intel Capital's check signals strategic interest from the world's largest semiconductor company at a moment when quantum is moving from research to commercial fabrication. In-Q-Tel, the CIA-affiliated strategic investor, rarely backs European hardware, and its participation marks US intelligence-community alignment with a non-US supplier.

Dutch deep-tech specialists FORWARD.one and Invest-NL Deep Tech Fund provide local industrial gravity, while ETF Partners brings sustainable-tech infrastructure experience. The syndicate is purpose-built for a multi-year capex-heavy buildout, not a software flip.

Company and Leadership

QuantWare was spun out of QuTech in 2020 by CEO Matt Rijlaarsdam and CTO Alessandro Bruno. QuTech, the joint Delft University and TNO institute, is one of the three or four most credible quantum research labs in the world, and the founding team brought direct lineage from that program into a commercial supplier model.

Rijlaarsdam has run the company on a merchant-supplier thesis since day one, refusing the more fashionable full-stack route that competitors pursued. That discipline is now paying off in customer count.

Problem and Opportunity

Most quantum computing companies build the full stack: hardware, control electronics, software, and end-user applications. The problem is that this forces every player to solve fabrication, cryogenics, error correction, and algorithms in parallel, with capital that can only stretch so far.

Research labs and emerging quantum firms need world-class processors but can't justify building their own fabs. That gap is exactly what QuantWare fills, and it grows wider as more quantum applications come online.

Product and Technology

QuantWare designs and fabricates superconducting quantum processing units. Its proprietary VIO (Vertical Integrated Open) architecture moves qubits off the planar 2D layouts that constrain IBM and Google designs, opening a route to much higher qubit counts. The newly announced VIO-40K targets 10,000 qubits, a threshold close to where fault-tolerant computation becomes feasible.

The commercial proof is in shipments. QuantWare has delivered QPUs to more than 50 customers across 20 countries, more than any other dedicated processor supplier. Each deployed chip generates fabrication and performance data that compounds the company's process advantage.

Use of Proceeds and Vision

The round funds KiloFab, a new Delft facility that will multiply current fabrication capacity by roughly 20x and become the world's largest dedicated open-architecture quantum fab. Capital also goes toward scaling VIO toward the VIO-40K milestone, expanding global customer support, and hiring engineers.

The strategic bet is that quantum will bifurcate the way classical semiconductors did, splitting into merchant hardware suppliers and full-stack systems companies. QuantWare wants to be the Intel of quantum, selling to everyone instead of competing with them.

Market Context

Global quantum spending is projected to clear $5B by 2027. The competitive set includes IBM and Google running full-stack programs, IonQ and Rigetti as public superconducting and trapped-ion players, Atom Computing in neutral atoms, and PsiQuantum's $750M photonic bet. Each of those operates as a closed system. QuantWare's non-conflicted supplier role gives it access to customers the full-stack vendors can't sell to.

Case Studies

Startups like yours already closed their rounds with us.

Founders across every stage and industry. Here's what it took.

• Raised $7.6M for Swiipr Technologies
• Raised $0.5M for Ap Tack
• Raised €0.5M for Ivent Pro

Read their stories →

2. Aignostics Receives $30M EIC STEP Scale Up Investment For AI Drug Development

Deal Overview

• Stage: Series B+ (EIC equity)
• Sector: Healthtech, AI-driven drug development
• Geography: Germany
• Round size: $30M
• Investor: European Innovation Council (STEP Scale Up scheme)

Investor Profile

The European Innovation Council's STEP Scale Up scheme is the EU's vehicle for keeping strategic technology companies on European soil. Selection signals both technical credibility and policy alignment with EU sovereignty priorities in biotech and AI.

EIC equity backing typically comes alongside private syndicates and acts as patient, non-dilutive-adjacent capital that gives founders runway without forcing premature exits.

Company and Leadership

Aignostics operates out of Germany and applies AI to drug development workflows. The company sits at the intersection of computational pathology and pharmaceutical R&D, a category where European research depth has historically outpaced commercial output.

Problem and Opportunity

Drug development cycles still run a decade and cost billions per approved compound. AI applied to target discovery, biomarker identification, and clinical trial design can compress timelines and improve hit rates, but only when paired with proprietary data and regulatory-grade rigor.

Product and Technology

Aignostics builds AI tools that support pharma partners in identifying targets and biomarkers. The work draws on computational pathology, which combines digital tissue imaging with machine learning to surface signals invisible to manual review.

Use of Proceeds and Vision

EIC equity will fund product scale-up, expansion of pharma partnerships, and continued investment in the underlying AI platform. The longer-term vision is to be embedded in the standard workflow for pre-clinical and translational drug discovery.

Market Context

AI for drug development is one of the most active healthtech subcategories of 2026, with competition from Recursion, Insitro, Owkin, and BenevolentAI. European players have a structural edge in computational pathology because of access to large public-hospital tissue archives and stronger data-governance frameworks than US counterparts.

Lessons For Founders

• Strategic investors signal more than capital. Intel Capital and In-Q-Tel on QuantWare's cap table tell customers and competitors that the technology has been vetted at the highest level of industry and government.
• Merchant-supplier positioning beats full-stack ambition in capital-intensive frontier hardware. Selling to everyone is a wider moat than competing with everyone when fabrication economics dominate.
• European sovereign capital is real and accessible. The EIC STEP Scale Up scheme and Invest-NL Deep Tech Fund are writing checks that match private growth rounds for companies that fit strategic priorities.
• Shipping commercially matters more than benchmark claims. QuantWare's 50+ customers across 20 countries did more for its Series B than any qubit-count headline could.
• Pick a thesis and hold it. QuantWare resisted the full-stack pull for five years and now sits in a category of one. Discipline compounds when the rest of the market is chasing the same story.